Investment
Features
FeesSafety
Academy
More
Pluang+

Compare H2O America (HTO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

H2O AmericaTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

H2O America vs Recursion Pharmaceuticals Inc — how do they compare? H2O America trades at $62.3 (market cap $2.61B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: H2O America is the larger of the two by market cap, and H2O America pays a 2.83% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

HTORXRX
Market Cap
$2.61B$1.81B
Sector
TechnologyHealth
52-Week High
$65.43$6.79
52-Week Low
$44.44$2.84
Enterprise Value
$4.40B$1.33B
Dividend Yield
2.83%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

H2O America

HTO trades at $62.57, up 2.16% with bullish technical signals and strong analyst support. The stock shows solid fundamentals with 12.91% net margin and consistent earnings beats in recent quarters. Recent transformative acquisitions in Texas water utilities drive growth potential, though execution risks and share dilution from equity issuance present challenges. Technical indicators show bullish momentum with key resistance at $63 and support at $61.

Outlook remains positive with 83% analyst buy ratings and $69.50 consensus target offering 11% upside. Dividend sustainability and acquisition integration are key watchpoints. Risks include execution challenges from Quadvest deal and potential EPS dilution from recent 11M share issuance.

Recursion Pharmaceuticals Inc

RXRX trades at $3.29, showing no change in the last session. The stock exhibits a bullish technical signal with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported a Q2 2026 loss of $0.25 per share, missing estimates, with revenues declining year-over-year. Recent news highlights ongoing investor conferences and partnership advancements, such as Genentech optioning a neuroscience target, but profitability remains a challenge with a net income margin of -961.97% for 2026.

The outlook for RXRX is mixed, with analyst consensus leaning hold (60%) due to high cash burn and unproven commercial scalability. Investment opportunity lies in its AI-driven drug discovery platform and partnerships, but risks include sustained losses, competitive pressures, and reliance on milestone payments. The stock's trajectory hinges on pipeline success and cost management improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About H2O America

H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.

Read more on HTO

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX